Trial Profile
A Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of JNJ-54175446 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Jan 2020
Price :
$35
*
At a glance
- Drugs JNJ 54175446 (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Janssen-Cilag
- 22 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 23 Jun 2015 New trial record